The open question I would have is, will the Phase I a/b trial next year be the clinical data that the market/partners want, or will we have to wait until Phase II data for proper validation?
As mentioned a few comments up, IF we don't get high subscriptions to the options, what exactly is the plan B.. I'm sure this came up while the strategy was being developed. The optimist in me thinks that the RACE team are confident enough in the funded trial to believe that in and of itself it will able to push partnerships and further raises through. The pessimist in me simply needs some kind of rerate in 2024 to justify my sunk costs over the years. FIC BIC isn't a permanent attribute!
The open question I would have is, will the Phase I a/b trial...
-
- There are more pages in this discussion • 2,243 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add RAC (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.57 |
Change
0.050(3.29%) |
Mkt cap ! $274.4M | |||
| Open | High | Low | Value | Volume |
| $1.56 | $1.61 | $1.56 | $72.59K | 45.80K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 7920 | $1.57 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.59 | 3500 | 2 |
View Market Depth
| Last trade - 12.58pm 08/11/2024 (20 minute delay) ? |
| RAC (ASX) Chart |